Try our Advanced Search for more refined results

In Re: Opana ER Antitrust Litigation

  1. June 04, 2021

    Classes Get Cert., Lose State Law Claims In Opana MDL

    An Illinois federal judge on Friday certified two classes of painkiller Opana ER purchasers in multidistrict litigation over a pay-for-delay scheme Endo Pharmaceuticals allegedly entered to keep a generic version off the shelves, but he nixed the state law claims from their case.

  2. April 21, 2021

    Impax, Endo Say FTC's Win Doesn't Help Opana Buyers

    Endo Pharmaceuticals Inc. and Impax Laboratories Inc. told an Illinois federal court that buyers who say they overpaid for Opana ER have to show more than the Federal Trade Commission did when it secured a Fifth Circuit win last week over the alleged delay of generic versions of the drug.

  3. April 16, 2021

    Opana Buyers Point To FTC's 5th Circ. Win Against Impax

    Buyers who say they overpaid for prescription painkiller Opana ER want the Illinois federal judge overseeing their case to look at a recent Fifth Circuit ruling that upheld the Federal Trade Commission's antitrust findings against a generic-drug maker over the same medication.

  4. November 20, 2019

    Buyers Chide Endo's Claim That Class Too Small For Cert. Bid

    Direct purchasers who claim they overpaid for pain reliever Opana ER have asked an Illinois federal court to ignore Endo Pharmaceuticals' argument that their proposed class is too small to be certified, asserting that federal courts routinely approve classes of fewer than 40, including in similar antitrust disputes.

  5. September 13, 2019

    Endo Says Drop Direct Buyers' Cert. Bid In Pay For Delay Row

    Endo Pharmaceuticals has urged an Illinois federal judge to toss a class certification bid by direct buyers of medication in multidistrict litigation who claim they overpaid for the painkiller Opana ER, saying the proposed class is too small to be certified.

  6. April 09, 2019

    Opana Buyers Seek Class Cert. In Pay-For-Delay Row

    Medication buyers who claim they overpaid for the painkiller Opana ER are asking an Illinois federal judge to certify two classes among them as part of multidistrict litigation over what they describe as a pay-for-delay scheme to keep a generic version off the shelves.

  7. May 07, 2018

    Opana ER MDL Buyers Want Impax Docs About Endo Deal

    Impax should be ordered to cough up details of the generic-drug maker's deal with brand-maker Endo that staved off generic competition to Endo's Opana ER, drug purchasers told the Illinois federal judge overseeing their multidistrict antitrust litigation against the companies, according to the latest brief in a heated discovery process.

  8. August 11, 2016

    Endo, Impax Face Leaner Opana Pay-For-Delay MDL

    An Illinois federal judge trimmed claims from a pay-for-delay multidistrict litigation alleging drugmakers Endo and Impax teamed up to keep Opana ER prices high, finding Thursday that indirect purchasers of the opioid cannot bring claims under three states' unjust enrichment laws.

  9. May 10, 2016

    Endo, Impax Can't Trim Opana Pay-For-Delay MDL, Class Says

    End-payors fought to keep alive state antitrust claims in litigation accusing pharmaceutical giants Endo and Impax of a pay-for-delay scheme involving opioid pain drug Opana ER, telling an Illinois federal judge Monday the drug companies are recycling old arguments.

  10. April 11, 2016

    Endo, Impax Move To Trim Opana Pay-For-Delay MDL

    Pharmaceutical giants Endo and Impax urged an Illinois federal court Friday to partially dismiss state antitrust claims refiled by a putative class of end-payors who allege in multidistrict litigation that the pair engaged in a pay-for-delay scheme involving a generic version of the opioid pain medication Opana ER.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!